AKT1 and hepatocellular carcinoma: In conclusion, our study demonstrated for the first time that sCLU activated AKT/GSK3β/β-catenin axis, followed by inducing chemoresistance, metastasis, CSC phenotype, and even poor prognosis of HCC patients.